Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01956903
Other study ID # CSM/EICH2010
Secondary ID 2010-020947-11
Status Completed
Phase Phase 1/Phase 2
First received September 30, 2013
Last updated September 30, 2013
Start date January 2010
Est. completion date September 2013

Study information

Verified date September 2013
Source Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Contact n/a
Is FDA regulated No
Health authority Spain: Agencia Española de Medicamentos y Productos Sanitarios
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of sequential infusion of allogenic mesenchymal stem cells (MSC) expanded "in vitro" in treating patients with acute graft-versus-host disease refractory to first-line therapy.


Description:

1. Ethical considerations:

- The study will be conducted in accordance with the requirements expressed in the Declaration of Helsinki (Hong Kong revision, September 1989) and following the recommendations of the Good Clinical Practice of the Clinical Trials (document 111/3976/88, July 1990 ) and Spanish legislation (Royal Decree 561/1993, published in April 16th Official State Bulletin "BOE"; May 13th, 1993) laying down the requirements for conducting clinical drug trials.

- Every subject will receive a written document called "Patient Information Sheet" that contains information about the following aspects of clinical trial: a) Aim of the study, methodology, study treatment and alternative therapies, expected benefits for himself or society, risks of the study and possible adverse events, number of visits and additional tests.

b) Voluntary nature of their participation and ability to withdraw at any time, without thereby altering the doctor-patient relationship.

c) People who have access to the data of the volunteer and how they maintain the confidentiality of the data.

d) How to contact with the investigator if necessary.

- The investigator will obtain the informed consent of the subject or, failing that, from a legal representative. The subject is preferably expressed written consent or, alternatively, orally to the research team independent witnesses who declare in writing under its responsibility.

- The person participating in the clinical trial or his representative may revoke the consent at any time.

2. Data Access:

- In order to ensure the confidentiality of the trial data, only have access to them, the researcher and his team, the test monitor and the Clinical Research Ethics Committee of the corresponding center or purposes under test and relevant health authorities.

- Protection of data: The content of the data collection forms and the documents generated during the study, will be protected from unauthorized uses by people outside the research and, therefore, will be considered strictly confidential and will not be disclosed to third parties except to those specified in the preceding paragraph.

3. Data Collection:

- Data colection forms will be dated and signed by the authorized principal investigator.

- Unknown data will be collected as "NA"(not available).

- Unusual or extreme results, or that do not match the expected sequence will be checked and corrected by initialing, signing and providing an explanation.

- Laboratory results that exceed normal limits established by the laboratory of the center, should be checked by the researcher and their significance will be noted next to the data, by initialing and signing.

4. Statistical Analysis:

- Baseline data will be analyzed using descriptive statistics and demographics (mean, median, standard deviation, minimum, maximum, and number of valid cases) for quantitative variables and absolute and relative frequencies for categorical variables.

- The primary efficacy objective is to determine the response rate of graft versus host disease (confidence intervals 95%).

- The primary safety objective is to determine the incidence of adverse events and toxicity related to the administration of the CSM (confidence intervals 95%).

- Secondary objectives: analyze overall survival and disease-free survival by the Kaplan-Meier method.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients with hematologic malignancies who have undergone allogenic stem cell transplantation and who are diagnosed with acute graft-versus-host-disease refractory to first-line treatment.

- Patients must have adequate cardiac function without evidence of uncontrolled hypertension, congestive heart failure or myocardial infarction within 6 months prior to the process.

- Adequate pulmonary function with no evidence of severe obstructive or restrictive pulmonary disease.

- Be able to understand the information and sign the informed consent.

Exclusion Criteria:

- Patients with uncontrolled disease or in progress at the time of treatment.

- Patients with uncontrolled bacterial, viral or fungal infection.

- Patients with inadequate cardiac or pulmonary function.

- Patients who do not have the required donor.

- Women pregnant or at risk of pregnancy by inadequate contraceptive measures.

- Patients who in the opinion of the investigator are not able to participate in the study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Genetic:
Allogenic Mesenchymal Stem Cell
Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, "Agencia Española de Medicamentos y Productos Sanitarios" with number 06-076)

Locations

Country Name City State
Spain Grupo Espanol de trasplantes hematopoyeticos y terapia celular Madrid

Sponsors (1)

Lead Sponsor Collaborator
Grupo Espanol de trasplantes hematopoyeticos y terapia celular

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse effects Infusion related.
Infection Rate.
from infusion to 100 days after stem cell transplant Yes
Secondary efficacy Acute Graft-Versus-Host Disease response rate. Acute Graft-Versus-Host Disease period (100 days) No
See also
  Status Clinical Trial Phase
Completed NCT02991846 - A Prospective Observational Study for Evaluating CGVHD
Recruiting NCT02291770 - Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells Phase 3
Terminated NCT01226420 - Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease Phase 2
Active, not recruiting NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01862965 - Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus Phase 2
Completed NCT02411474 - Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD N/A
Completed NCT02040623 - Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) Phase 2
Active, not recruiting NCT01158105 - Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) Phase 2
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Active, not recruiting NCT01366092 - Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 2
Not yet recruiting NCT06458127 - Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease N/A
Recruiting NCT05690971 - Psychosocial Mobile App for Chronic Graft-Versus-Host Disease N/A
Recruiting NCT02918188 - Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD Phase 2
Recruiting NCT01765660 - Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease Phase 2
Terminated NCT03584516 - GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Phase 2/Phase 3
Recruiting NCT04692376 - MSC for Treatment of cGVHD After Allo-HSCT Phase 2
Completed NCT02966301 - Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Phase 2
Terminated NCT01898377 - Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children Phase 2
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2